Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 95 clinical trials
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis and

cell transplantation
myelofibrosis
  • 0 views
  • 17 Sep, 2021
  • 10 locations
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.

g-csf
essential thrombocythemia
thrombocytosis
erythropoietin
platelet count
  • 13 views
  • 25 Jan, 2021
  • 1 location
  • 0 views
  • 01 Apr, 2021
  • 2 locations
A Safety Trial of Fedratinib in Subjects With DIPSS Intermediate or High-Risk Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia

(PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (post-ET MF) and Previously Treated with Ruxolitinib including a Sub-study with concomitant

essential thrombocythemia
thrombocytosis
luspatercept
anemia
polycythemia
  • 72 views
  • 31 Aug, 2021
  • 41 locations
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

inhibitor such as ruxolitinib before a donor stem cell transplant may help reduce symptoms of myelofibrosis such as inflammation and enlargement of the spleen, improve the patient's general physical

janus kinase inhibitor
melphalan
total body irradiation
carbon monoxide
mycophenolate mofetil
  • 139 views
  • 11 Jul, 2021
  • 1 location
Inflammatory Signal Inhibitors for COVID-19 (MATIS)

The Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS) study is a two-stage, open-label, randomised controlled trial assessing the efficacy of ruxolitinib (RUX) and

pneumonia
covid-19
  • 7 views
  • 11 Sep, 2021
  • 1 location
Actuate 1901: 9-ING-41 in Myelofibrosis

9-ING-41 has anti-cancer clinical activity while not causing myelosuppression, and has both pre-clinical anti-fibrotic activity and activity against myelofibrosis. This Phase 2 study will study its efficacy in patients with advanced myelofibrosis.

stem cell transplantation
ruxolitinib
cancer
neutrophil count
  • 17 views
  • 19 Mar, 2021
  • 10 locations
Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)

The only curative treatment for patients with myelofibrosis (MF) is allogeneic stem cell transplantation (SCT). Treatment with JAK2 inhibitors like pacritinib improves condition of MF patients, decreases spleen size and might diminish graft-versus-host disease (GvHD), thereby improving the outcome of SCT.

stem cell transplantation
pacritinib
graft versus host disease
  • 24 views
  • 03 Sep, 2021
  • 21 locations
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.

cytarabine
ifosfamide
imatinib
fludarabine
cancer
  • 0 views
  • 24 Jan, 2021
  • 1 location
Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy

EBV-HLH and CAEBV are both caused by EBV infection, part of them can rapidly lead to a syndrome of severe, life-threatening hyper-inflammation, with poor prognosis. Currently, the most effective treatment remains unknown. This study is trying to evaluate the efficacy and safety of PD-1 monoclonal antibody as a first-line therapy …

  • 0 views
  • 15 Sep, 2021
  • 1 location